1 Background: We recently reported that the skin sympathetic nerve activity (SKNA) can 2 be used to estimate the sympathetic tone in humans. In animal models, vagal nerve 3 stimulation (VNS) can damage the stellate ganglion, reduce stellate ganglion nerve 4 activity and suppress cardiac arrhythmia. Whether or not VNS can suppress 5 sympathetic tone in humans remain unclear. 6 Objective: To test the hypothesis that VNS suppresses SKNA in patients with drug 7 resistant epilepsy. 8
Vagal nerve stimulation (VNS) is commonly used to manage patients with drug resistant 2 epilepsy and has been reported to reduce the incidence of sudden unexpected death in 3 epilepsy (SUDEP). 1, 2 Recent studies showed that there is significant interictal cardiac 4 electrical instability (elevated T wave alternans) in patients with drug-resistant epilepsy, 5 which was effectively suppressed by VNS. 3 Because T wave alternans is enhanced by 6 sympathetic activation, 4 these findings suggest that VNS might be associated with 7 reduced sympathetic tone. Consistent with that hypothesis, Clancy et al 5 reported that 8 non-invasive stimulation of the auricular branch of the vagal nerve suppressed muscle 9 sympathetic nerve activity in normal human volunteers. However, as far as we know, 10 there was no study that demonstrated reduced sympathetic nerve activity in patients 11 with chronically implanted vagal nerve stimulators. The cervical and thoracic vagal 12 nerves contain significant sympathetic components. 6, 7 In ambulatory dogs, left cervical 13 VNS could be associated with high rate of activation of the left stellate ganglion. 8
14
Repeated high rate of excitation might cause neurotoxicity and promote neuronal cell 15 death. 9 Consistent with the neurotoxicity hypothesis, we recently reported that there 16 was significant damage to the left stellate ganglion in dogs receiving chronic VNS. 10 The 17 stellate ganglion damage was associated with a significant reduction of the stellate 18 ganglion nerve activity and ventricular rate in atrial fibrillation (AF). However, it is difficult 19 to record the stellate ganglion nerve activity in humans. We recently developed a new 20 method (neuECG) to simultaneously record the skin sympathetic nerve activity (SKNA) 21 and electrocardiogram (ECG) in ambulatory dogs. 11, 12, 13 and in humans. 14 University (IU) School of Medicine. We prospectively enrolled 26 patients with drug 6 resistant epilepsy to participate in the study. All patients were recruited after they were 7 admitted to the Epilepsy Monitoring Unit of the IU-Methodist Hospital to record video 8 electroencephalogram. As part of the standard care, anti-epileptic medications were 9 completely or partially withdrawn while the patients were confined to bed with bathroom 10 privileges. The recordings were made continuously except when the patients went to 11 the bathroom. The neuECG was recorded using standard ECG patch electrodes 12 connected to a modified ME6000 (Biomation, Almonte, Ontario) recorder with a wide 13 bandwidth (2 KHz) and high sampling rate (10 KHz). All 26 patients had at least 24-hr of 14 recording (Table 1) . Among them, six had previously underwent VNS implantation, while 15 20 did not receive it. The standard VNS protocol was 30 s on and 3-5 min off. 15
16
Because this is an observational study, the off-time was variable based on the clinical 17 needs. The baseline SKNA of 19 patients in the latter group was included in a previous 18 report. 14 A total of 8 patients had seizure during the recording period. We excluded the 19 data recorded 40-min before to 40-min after the seizure from analyses. Because VNS causes large artifacts on the neuECG recording, we only analyzed data 1 during the VNS-off time. The data were analyzed with a custom written software which 2 selected the R waves and calculated the RR intervals and heart rate automatically. All 3 selections were then confirmed by manual examination to exclude artifacts. The 4 average SKNA (aSKNA) and heart rate were determined for 2 min at the beginning, 20-5 min past and 40-min past the hour for 24 hours, resulting in 72 data points per patient. If 6 the patient went to the bathroom during the analyses window, we used the data 7 acquired after the resumption of recording for analyses. We bandpass filtered the 8 recorded neuECG signals between 200 Hz to 1000 Hz and also between 500 Hz to 9 1000 Hz to display SKNA. As shown in our previous report, 14 the sensitivity of detecting 10 SKNA is higher with the former filter setting but the specificity is higher with the latter 11 filter setting. The same signals were bandpass filtered between 0.5 Hz and 150 Hz to 12 display the surface ECG. For quantitative analyses, we integrated all digitized SKNA 13 signals over each 1-min window and divided the results (in µV) by the number of 14 samples in that window (10,000 X 60, or 60,000 samples) to obtain the aSKNA. The Linear regression was used to study the relationship between heart rate and SKNA 4 activity for each patient. Linear mixed-effects models were used to compare SKNA 5 activity between control and VNS stimulation groups where patients were treated as 6 random effects. Generalized additive mixed-effects models were used to characterize 7 the circadian pattern. T test was used to compare average SKNA activities and heart 8 rate (over 24-hour period), and the correlation coefficients between SKNA and heart 9 rate. Two-sided p values ≤0.05 were considered statistically significant. The VNS group included 6 patients (2 men, age 40±11 years). The control group 13 included 20 patients (7 men, age 37±8 years) ( Table 1) . None of the patients had which were also associated with heart rate elevation. The data from the red rectangles 6 were enlarged and shown in Panel D. These SKNA episodes were not pulse 7 synchronous and were morphologically similar to that recorded from the superficial 8 branches of radial nerves with microneurography techniques. 16 The artifacts on surface 9 ECG (red dots) suggest that some of the SKNA episodes occurred coincidentally with 10 the physical activity. There was a positive correlation between heart rate and SKNA in all patients studied. 5 We tested the correlation using two different filter settings for SKNA detection. filter setting, the aSKNA in Lead I was 1.02 µV (CI 0.92 to 1.12) in VNS group and 1.69 1 µV (CI 1.29 to 2.09) in non-VNS group (p=0.049). The aSKNA in Lead II was 1.08 µV 2 (CI 1.04 to 1.12) in VNS group and 1.57 µV (CI 1.34 to 1.81) in non-VNS group 3 (p=0.015). Therefore, excluding hypertensive patients did not change the conclusion of 4 the study. The results of the present study show that patients with left VNS had lower heart rate 8 and aSKNA than patients without VNS. These findings suggest that chronic intermittent 9 VNS can reduce sympathetic tone in humans. 
Mechanisms of VNS 21
The vagal nerve is a complex anatomical structure. It is generally accepted that 22 parasympathetic activation is responsible for some of the therapeutic effects of VNS. Skin sympathetic nerve recording 13 The skin is well innervated by sympathetic nerve fibers. 29, 30 The somata of the nerves in 14 the upper extremities and thorax resides in the cervical and stellate ganglia. 31 Our 15 recent studies showed that SKNA could be detected in humans using conventional 16 patch electrodes using a recording system with high sampling rate and wide frequency was more specific but might be less sensitive in detecting the SKNA. We have therefore 1 used both filter settings to detect nerve activity in the present study. With either filter 2 setting, we were able to document robust SKNA in control patients and reduced SKNA 3 in patients with VNS. These findings suggest that, similar to VNS in ambulatory dogs, 10 4 VNS in humans also suppresses sympathetic tone and maybe potentially useful in 5 cardiac arrhythmia control. The heart rate is controlled by both sympathetic and parasympathetic nerve activities.
9
While the SKNA is a useful measure of sympathetic tone, it does not adequately 10 measure all nerve activities that control the sinus node. Therefore, the average 11 correlation coefficient between aSKNA and heart rate was around 0.45-0.72 in different 12 groups and using different filter settings. Similar correlation coefficients were also 13 observed between sympathetic nerve activities and heart rate in ambulatory dogs. 11 It 14 is unclear why VNS patients had reduced heart rate responses to SKNA. However, 15 because VNS may damage the stellate ganglion and reduce sympathetic outflow, 10 the 16 damaged stellate ganglion might not be able to generate enough sympathetic tone to 17 overcome the parasympathetic influence of the sinus node. Limitations of the study 20 We do not have the histological sections or direct recordings of the stellate ganglion in Stimul. 2014;7:871-877. 10
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